155 related articles for article (PubMed ID: 15750629)
1. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.
Jones LP; Li M; Halama ED; Ma Y; Lubet R; Grubbs CJ; Deng CX; Rosen EM; Furth PA
Oncogene; 2005 May; 24(22):3554-62. PubMed ID: 15750629
[TBL] [Abstract][Full Text] [Related]
2. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.
Jones LP; Tilli MT; Assefnia S; Torre K; Halama ED; Parrish A; Rosen EM; Furth PA
Oncogene; 2008 Jan; 27(6):794-802. PubMed ID: 17653086
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness of
Alothman SJ; Wang W; Goerlitz DS; Islam M; Zhong X; Kishore A; Azhar RI; Kallakury BV; Furth PA
Cancer Prev Res (Phila); 2017 Apr; 10(4):244-254. PubMed ID: 28283467
[TBL] [Abstract][Full Text] [Related]
4. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
5. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma.
Tilli MT; Frech MS; Steed ME; Hruska KS; Johnson MD; Flaws JA; Furth PA
Am J Pathol; 2003 Nov; 163(5):1713-9. PubMed ID: 14578170
[TBL] [Abstract][Full Text] [Related]
6. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
[TBL] [Abstract][Full Text] [Related]
7. The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
Nakles RE; Kallakury BV; Furth PA
Am J Pathol; 2013 Jun; 182(6):1976-85. PubMed ID: 23664366
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Dabydeen SA; Kang K; Díaz-Cruz ES; Alamri A; Axelrod ML; Bouker KB; Al-Kharboosh R; Clarke R; Hennighausen L; Furth PA
Carcinogenesis; 2015 Jan; 36(1):122-32. PubMed ID: 25421723
[TBL] [Abstract][Full Text] [Related]
9. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
[TBL] [Abstract][Full Text] [Related]
10. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Ma Y; Katiyar P; Jones LP; Fan S; Zhang Y; Furth PA; Rosen EM
Mol Endocrinol; 2006 Jan; 20(1):14-34. PubMed ID: 16109739
[TBL] [Abstract][Full Text] [Related]
11. MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas.
Mukherjee M; Ge G; Zhang N; Edwards DG; Sumazin P; Sharan SK; Rao PH; Medina D; Pati D
Oncogene; 2014 Nov; 33(48):5511-5522. PubMed ID: 24276237
[TBL] [Abstract][Full Text] [Related]
12. BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
van de Ven M; Liu X; van der Burg E; Klarenbeek S; Alexi X; Zwart W; Dijcks F; Bouwman P; Jonkers J
J Pathol; 2018 Sep; 246(1):41-53. PubMed ID: 29877575
[TBL] [Abstract][Full Text] [Related]
13. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
14. Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.
Herynk MH; Lewis MT; Hopp TA; Medina D; Corona-Rodriguez A; Cui Y; Beyer AR; Fuqua SA
Oncogene; 2009 Sep; 28(36):3177-87. PubMed ID: 19561644
[TBL] [Abstract][Full Text] [Related]
15. Retroviral transduction of splice variant Brca1-Delta11 or mutant Brca1-W1777Stop causes mouse epithelial mammary atypical duct hyperplasia.
Bachelier R; Vincent A; Mathevet P; Magdinier F; Lenoir GM; Frappart L
Virchows Arch; 2002 Mar; 440(3):261-6. PubMed ID: 11889595
[TBL] [Abstract][Full Text] [Related]
16. Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice.
Miermont AM; Cabrera MC; Frech SM; Nakles RE; Diaz-Cruz ES; Shiffert MT; Furth PA
Anat Physiol; 2012 Jun; Suppl 12():. PubMed ID: 24575359
[TBL] [Abstract][Full Text] [Related]
17. Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.
Bowen TJ; Yakushiji H; Montagna C; Jain S; Ried T; Wynshaw-Boris A
Cancer Res; 2005 Oct; 65(19):8736-46. PubMed ID: 16204043
[TBL] [Abstract][Full Text] [Related]
18. Tumor formation in Brca1 conditional mutant mice.
Deng CX
Environ Mol Mutagen; 2002; 39(2-3):171-7. PubMed ID: 11921186
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.
Zheng L; Annab LA; Afshari CA; Lee WH; Boyer TG
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9587-92. PubMed ID: 11493692
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis.
Medina D; Kittrell FS; Hill J; Shepard A; Thordarson G; Brown P
Cancer Res; 2005 Apr; 65(8):3493-6. PubMed ID: 15833886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
